412 related articles for article (PubMed ID: 29748183)
41. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
42. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
43. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
44. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
45. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
46. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
47. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
48. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
49. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
50. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
51. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
[TBL] [Abstract][Full Text] [Related]
53. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
54. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
[TBL] [Abstract][Full Text] [Related]
55. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
56. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
57. Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.
van Gulijk M; Belderbos B; Dumoulin D; Cornelissen R; Bezemer K; Klaase L; Dammeijer F; Aerts J
Int J Cancer; 2023 Apr; 152(7):1438-1443. PubMed ID: 36104949
[TBL] [Abstract][Full Text] [Related]
58. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
59. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
[TBL] [Abstract][Full Text] [Related]
60. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA
Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
